Ophthalmology Search
Ophthalmology Ophthalmology
primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.

Primary%20open-angle%20glaucoma Management

Follow Up

  • Primary open-angle glaucoma (POAG) patients require lifetime therapy and monitoring of intraocular pressure (IOP), visual fields and optic disc
  • Patients who underwent laser surgery should be evaluated within 30 minutes-2 hours post-surgery and follow-up done within 6 weeks after surgery
  • Patients who underwent incisional glaucoma surgery must be evaluated after 12-36 hours post-surgery and at least once during the first 1-2 weeks to assess IOP, visual acuity and status of the anterior segment
    • Follow-up is done after 3 months in patients without postoperative complications to evaluate IOP, visual acuity and anterior segment status
    • Patients with postoperative complications require more frequent visits
  • Follow-up visits are usually at least 2 times a year but frequency may depend on extent of damage, presence of progression, stability of IOP control and patient compliance
  • Measure visual acuity, IOP and perform slit-lamp biomicroscopy
  • Gonioscopy may be performed every 1-5 years but is warranted in cases of unexplained IOP changes or if with suspicion of angle-closure component or anterior chamber abnormalities
  • Indications for therapy adjustments include:
    • Failure to achieve target IOP
    • Progressive optic nerve damage despite achieving target IOP
    • Medication intolerance or patient has developed contraindications to the medications
    • Poor patient compliance
  • Poor control of IOP warrants adjustment of therapy for which a patient may be seen every 2-8 weeks
  • Consider increasing target IOP if the patient has been stable and either requires or desires less medication
  • Consider decreasing target IOP in the presence of visual field deterioration or progressive optic disc damage

Expert Referral

  • Consultation or referral to an ophthalmologist with special training or experience in glaucoma management
  • Patients with significant or progressive loss of vision may be referred for vision rehabilitation and social services

Vision Rehabilitation

  • Improves visual function with the use of optical and non-optical devices and includes occupational, vocational and independent living counseling services
  • Has been found to significantly improve vision-related quality of life of patients with glaucoma
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
New asthma guide: What doctors should know
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Telemedicine shows potential for managing patients requiring IV iron
Audrey Abella, 4 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.